



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

14th August, 2013

The Manager - Listing
Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001.

Mr. Hari K
Vice President
National Stock Exchange of India Ltd.
"Exchange Plaza,
Bandra - Kurla Complex
Bandra (E),
Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

We wish to inform you that the Board of Directors at their meeting held on today taken on record the Unaudited Financial Results (Standalone and Consolidated) and Report of Segment wise Revenue, Results and Capital employed for the Quarter ended 30th June, 2013 as per Clause 41 of the Listing Agreement along with Limited Review Report by the Statutory Auditors and press note. Please find enclosed a copy of the same for your information and records.

Board convened the 30th Annual General Meeting of the Members of the Company for the year 2012-2013 on Saturday, the 28th day of September, 2013 at 10.30 a.m. at Daspalla Hotel, Road No.37, Jubilee Hills, Hyderabad - 500 033. Pursuant to Section 154 of the Companies Act, 1956 the Register of Members and Transfer books of the company will remain closed from Wednesday, the 25th Day of September, 2013 to Saturday, the 28th day of September, 2013 (both days inclusive) for the purpose of Annual General Meeting of the company.


Board of Directors proposed the following items of business and recommended to the members for their approval:

1. Increase of Authorised Capital from Rs.35,00,00,000/- to Rs.40,00,00,000/- and consequential amendment of Memorandum and Articles of Association.
2. Proposed to issue further equity shares under section 81(1A) not exceeding 50,00,000 equity shares of Rs.10/- each to various persons /entities other than shareholders.
3. Increase of remuneration of Dr.P.Bhaskara Narayana, Director & CFO from Rs.32,00,000/- to Rs.36,00,000/-
4. Increase of remuneration of Dr.AKS Bhujanga Rao, President(R&D and Technical) from Rs.32,00,000/- to Rs.36,00,000/-

This is for your information and records.

Thanking you,

Yours faithfully,
for NATCO Pharma Limited


M Adinarayana

Company Secretary &
V.P. (Legal & Corporate Affairs)
Encl: as above.

C.C.to: (i) NSDL, Mumbai

(ii) CDSL, Mumbai



Statement of stand-alone Financial Results for the quarter ended 30th June, 2013

Rs. lakhs

PART I : STATEMENT OF STAND-ALONE RESULTS				
PARTICULARS	THREE MONTHS ENDED			YEAR ENDED (AUDITED)
	30-JUN-2013 REVIEWED	31-MAR-2013 UN-AUDITED	30-JUN-2012 REVIEWED	31-MAR-2013
01. Gross Sales / Income from Operations	14254	13536	11663	54656
Less : Excise Duty	291	435	478	2122
Less : Sales Tax	278	278	327	1101
Net Sales / Income from Operations	13685	12823	10858	51433
02. Other Operating Income	797	1508	504	4492
03. TOTAL INCOME FROM OPERATIONS	14482	14331	11362	55925
04. EXPENDITURE				
a) Cost of materials consumed	3871	4774	4438	18063
b) Purchases of stock-in-trade	-	70	195	658
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-275	-690	-1389	-2125
d) Employee benefits expense	2205	2087	1928	8536
e) Depreciation and amortization expense	641	536	432	1984
f) Other Expenses	4172	4688	3306	15201
TOTAL EXPENSES	10614	11465	8910	42217
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3868	2866	2452	13708
06. Other Income	350	203	301	1194
07. Finance costs	958	769	444	2512
08. Exceptional items	-	-	-	1158
08. Profit / (Loss) from ordinary activities before tax	3260	2300	2309	11232
09. Tax expense, including deferred tax	986	1128	491	3419
10. Net Profit / Loss (-) from ordinary activities after tax	2274	1172	1818	7813
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50621
13. Earnings per share – Basic and diluted EPS before and after extraordinary item (Rs.) – non-annualized	7.25 7.25	3.74 3.74	5.84 5.84	25.02 24.91
PART II : SELECT INFORMATION				
14. Public Shareholding:				
a) Number of Shares	13,607,593	13,594,593	13,378,081	13,594,593
b) Percentage of Shareholding	43.37	43.33	42.95	43.33
15. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered –				
b) Non – encumbered – No. of shares	17,765,481	17,778,481	17,769,881	17,778,481
Percentage (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
Percentage (as a % of the total share capital of the company)	56.63	56.67	57.05	56.67

Status of Investor Complaints as at 30th June, 2013

Pending as on 01-04-2013	Nil
Received during the quarter	58
Resolved during the quarter	58
Pending as on 30-06-2013	Nil

Dated at Hyderabad, this, the 14th day of August, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director



Statement of consolidated Financial Results for the quarter ended 30th June, 2013

Rs. lakhs

PART I : STATEMENT OF CONSOLIDATED RESULTS				
PARTICULARS (REFER NOTES BELOW)	THREE MONTHS ENDED (UNREVIEWED/UNAUDITED)			YEAR ENDED (AUDITED)
	30-JUN-2013	31-MAR-2013	30-JUN-2012	31-MAR-2013
01. Gross Sales / Income from Operations	17062	16156	14252	65302
Less : Excise Duty	323	430	478	2122
Less : Sales Tax	285	278	327	1101
Net Sales / Income from Operations	16454	15448	13447	62079
02. Other Operating Income	797	1283	637	4322
03. TOTAL INCOME FROM OPERATIONS	17251	16731	14084	66401
04. EXPENDITURE				
a) Cost of materials consumed	5745	4794	6511	17757
b) Purchases of stock-in-trade	-	1586	195	8714
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-275	-755	-1389	-2191
d) Employee benefits expense	2589	2539	2143	10229
e) Depreciation and amortization expense	731	625	443	2212
f) Other Expenses	4724	5143	3726	16900
TOTAL EXPENSES	13514	13932	11629	53621
05. Profit / (Loss) from Operations before other income, finance costs and exceptional items	3737	2799	2455	12780
06. Other Income	350	186	178	1241
07. Finance costs	996	823	467	2631
08. Exceptional item	-	-	-	1158
09. Profit / (Loss) from ordinary activities before tax	3091	2162	2166	10232
10. Tax expense, including deferred tax	1014	1321	491	3644
11. Minority Interest	101	-291	-32	-599
12. Net Profit / Loss (-) from ordinary activities after tax	2178	1132	1707	7187
13. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3137	3137	3115	3137
14. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year				50217
15. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.)	6.94	3.61	5.48	23.01
	6.94	3.61	5.48	22.91
PART II : SELECT INFORMATION				
16. Public Shareholding:				
a) Number of Shares	13,607,593	13,594,593	13,378,081	13,594,593
b) Percentage of Shareholding	43.37	43.33	42.95	43.33
16. Promoters and Promoter Group Shareholding				
a) Pledged / Encumbered - No. of shares	-	-	-	-
b) Non - encumbered - No. of shares	-	-	-	-
Percentage (as a % of the total shareholding of promoter and promoter group)	17,765,481	17,778,481	17,769,881	17,778,481
Percentage (as a % of the total share capital of the company)	100.00	100.00	100.00	100.00
	56.63	56.67	57.05	56.67

The above financial results were approved by the Audit Committee and the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 14th August, 2013. There are no exceptional and extraordinary items to be reported for the period under review. The stand-alone results are available on the company's web-site www.natcopharma.co.in. In respect of reference relating to non-accounting of minimum alternate tax credit, the company will review the position during the current financial year.

Dated at Hyderabad, this, the 14th August, 2013.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 30th June, 2013

Pending as on 01-04-2013	NA
Resolved during the quarter	58
Resolved during the quarter	58
Pending as on 30-06-2013	NA



Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter ended on 30th June, 2013

Rs. lakhs

	THREE MONTHS ENDED			PREVIOUS ACCOUNTING YEAR ENDED (UN-AUDITED)
	30-JUN-2013	31-MAR-2013	30-JUN-2012	
01. Segment Revenue (Net)				31-MAR-2013
a) Bulk Chemicals				
b) Formulations	6370	6562	3970	23692
c) Job Work	6488	7572	7056	29367
d) Unallocated	195	219	156	944
Total	1841	254	659	3244
Less : Inter-segment Revenue	14894	14807	11841	57247
Net Sales / Income from Operations	412	276	479	1322
02. Segment Results : Profit (+)/Loss (-) before tax and interest	14482	14331	11362	55925
a) Bulk Chemicals				
b) Formulations	1517	1541	653	5527
c) Job Work	2188	3136	2925	12235
d) Unallocated	139	129	116	728
Total	1673	223	591	2915
Less : a) Interest	5515	5029	4285	21405
b) Other allocable expenditure	958	769	444	2512
c) Unallocable Income	1647	2163	1833	8855
Total Profit Before Tax	(350)	(203)	(301)	(1194)
03. Capital Employed (Segment Assets - Segment Liabilities)	3260	2300	2309	11232
a) Bulk Chemicals				
b) Formulations	37370	36375	33382	36375
c) Job Work	30873	32742	29671	32742
d) Unallocated (Others)	156	94	118	94
Total	-12367	-15453	-14608	-15453
	58032	53758	48565	53758

The above un-audited financial results were reviewed by the Audit Committee, Statutory Auditors and approved by the Board of Directors at a meeting held at Hyderabad, on Wednesday, the 14th August, 2013. There are no extraordinary items to be reported for the period under review. In respect of non-accounting of minimum alternate tax credit, referred to in the review report, the company will evaluate the position during the current financial year. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. The figures for the quarter ended March 31, 2013 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures up to third quarter of the relevant financial year, except those relating to segment revenues and profitability.

Dated at Hyderabad, this, the 14th day of August, 2013,
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V. S. Nannapaneni
Chairman & Managing Director

Regd. Office: **NATCO** House, Road # 2, Banjara Hills, **Hyderabad : 500 033.**

Walker, Chandiook & Co

7th Floor, Block III, White House
Kundan Bagh, Begumpet
Hyderabad 500016
India

T +91 40 6630 8200
F +91 40 6630 8230
E HYDERABAD@in.gt.com

Limited Review Report

To the Board of Directors of NATCO Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of **NATCO Pharma Limited** ("the Company") for the quarter ended 30 June 2013, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. We have neither performed a review nor performed an audit of the figures/notes for the consolidated results for the quarters ended 30 June 2013, 31 March 2013 and 30 June 2012 as reported in the Statement and accordingly do not express any opinion thereon.

